Patent: 10,047,033
✉ Email this page to a colleague
Summary for Patent: 10,047,033
Title: | Compositions comprising oxo-derivatives of fatty acids and methods of making and using same |
Abstract: | The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA. |
Inventor(s): | Manku; Mehar (Birmingham, GB), Climax; John (Dublin, IE), Coughlan; David (Dublin, IE) |
Assignee: | DS BIOPHARMA LIMITED (Dublin, IE) |
Application Number: | 15/153,476 |
Patent Claims: | see list of patent claims |
Details for Patent 10,047,033
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | NUCALA | mepolizumab | For Injection | 125526 | 11/04/2015 | ⤷ Try a Trial | 2035-05-13 |
Glaxosmithkline Llc | NUCALA | mepolizumab | Injection | 125526 | 06/06/2019 | ⤷ Try a Trial | 2035-05-13 |
Glaxosmithkline Llc | NUCALA | mepolizumab | Injection | 125526 | 01/22/2022 | ⤷ Try a Trial | 2035-05-13 |
Glaxosmithkline Llc | NUCALA | mepolizumab | For Injection | 761122 | 06/06/2019 | ⤷ Try a Trial | 2035-05-13 |
Glaxosmithkline Llc | NUCALA | mepolizumab | Injection | 761122 | 06/06/2019 | ⤷ Try a Trial | 2035-05-13 |
Glaxosmithkline Llc | NUCALA | mepolizumab | Injection | 761122 | 01/22/2022 | ⤷ Try a Trial | 2035-05-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |